Search results
Results from the WOW.Com Content Network
Ciprofloxacin is weakly bound to serum proteins (20–40%). It is an inhibitor of the drug-metabolizing enzyme cytochrome P450 1A2, which leads to the potential for clinically important drug interactions with drugs metabolized by that enzyme. [5] Ciprofloxacin is about 70% available when administered orally. [3]
Fluoroquinolones are often used for genitourinary tract infections [5] and are widely used in the treatment of hospital-acquired infections associated with urinary catheters. In community-acquired infections , they are recommended only when risk factors for multidrug resistance are present or after other antibiotic regimens have failed.
Lymphedema is most frequently a complication of cancer treatment or parasitic infections, but it can also be seen in a number of genetic disorders. Tissues with lymphedema are at high risk of infection because the lymphatic system has been compromised. [3] Though incurable and progressive, a number of treatments may improve symptoms. [2]
The most reported adverse effects of phase I studies included headache, rhinitis, pain, dyspepsia, and dysmenorrhea. Investigators did not believe that any of these were directly treatment-related, as many of these events are considered symptoms or manifestations of the underlying illness. [5]
Chronic venous insufficiency (CVI) is a medical condition characterized by blood pooling in the veins, leading to increased pressure and strain on the vein walls. [1] The most common cause of CVI is superficial venous reflux, which often results in the formation of varicose veins, a treatable condition. [2]
The pathophysiology is not yet well understood. Leukocytoclastic vasculitis is proposed to be the underlying cause resulting in reactive lymphedema. [2] Prolonged standing with full knee extension and minimal movement for a prolonged period of time is postulated to induce a temporary failure in pumping the venous and lymphatic systems in the calf region leading to acute gravity-dependent ...
Lipedema was first identified in the United States, at the Mayo Clinic, in 1940. [ 32 ] [ 33 ] Most attribute the original identification of lipedema to E. A. Hines and L. E. Wold (1951). [ 32 ] Despite that, lipedema is barely known in the United States to physicians or to the patients who have the disease.
Milroy's disease is also known as primary or hereditary lymphedema type 1A or early onset lymphedema. It is a very rare disease with only about 200 cases reported in the medical literature. Milroy's disease is an autosomal dominant condition caused by a mutation in the FLT4 gene which encodes the vascular endothelial growth factor receptor 3 ...